SecBot SecBot
8-K ·Filed Aug 5, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001689375-26-000052
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monetize the near-term pipeline catalysts: ELEVATE-45-201 Cohort 1 data (Oct 2026) is the next binary event; positive functional data could re-rate the stock. Cash runway into Q3 2027 removes near-term financing risk. No financial guidance was provided, so focus on clinical execution.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.06
T+0 close · Aug 5, 2026 · via day close
Latest settled
−37.68%
T+60 · $4.40
Vs SPY
−37.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $7.06entry
  2. T+1 · 3mo ago −2.69%α −2.53% · $6.87
  3. T+5 · 3mo ago +8.64%α +8.29% · $7.67
  4. T+20 · 3mo ago +3.40%α +4.00% · $7.30
  5. T+60 · 19d ago −37.68%α −37.62% · $4.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics reported Q2 2026 results with collaboration revenue of $0.9M as the Vertex program winds down, and a GAAP net loss per share of -$1.01, beating the $-1.16 consensus by 12.9%. The company reiterated pipeline progress across its DMD franchise, with key data readouts for ELEVATE-45-201 Cohort 1 in October 2026 and ELEVATE-44-201 open-label data by year-end 2026. Cash of $223M provides runway into Q3 2027, but the significant year-over-year drop in collaboration revenue and ongoing operating losses keep the financial profile stable but unimproved.

Key Financial Metrics

EPS
−$1.01
est −$1.16 · +12.9%
Revenue
$898.0K
-53.9% YoY
Rating
beat

Key Facts

  • Q2 2026 GAAP EPS of -$1.01 vs consensus of -$1.16 (12.9% beat)
  • Collaboration revenue declined to $0.9M from $2.0M in Q2 2025 (-54%) due to Vertex program wind-down
  • Net loss was $42.8M vs $43.1M in the prior-year quarter, essentially flat
  • Cash, cash equivalents, and marketable securities were $223.0M as of June 30, 2026, down from $295.7M at year-end 2025
  • ELEVATE-44-201 Cohort 2 enrollment complete with data expected Q1 2027; Cohort 1 open-label data expected by year-end 2026
  • ELEVATE-45-201 Cohort 1 data expected in October 2026; DMC cleared dose escalation to 10 mg/kg
  • Vertex on track to report VX-670 Phase 1/2 data in H2 2026

Financial Impact

No material change in quarterly burn rate; revenue decline is expected as Vertex collaboration activities have largely completed. EPS beat is notable but driven by small absolute share count and low expectations for a pre-revenue biotech.

revenuenet_losscash

Risk Factors

  • Revenue will continue to decline to near-zero as Vertex collaboration winds down, leaving the company without recurring revenue
  • Clinical trial risk: Duchenne exon-skipping programs face high regulatory and efficacy hurdles
  • Cash burn of ~$36M per quarter implies potential need for financing before mid-2027 if milestones are delayed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001689375-26-000052
Document: trda-20260805.htm0001689375-26-000052
Document: 0001689375-26-000052-index-headers.html0001689375-26-000052
Document: 0001689375-26-000052-index.html0001689375-26-000052
Document: 0001689375-26-000052.txt0001689375-26-000052
8-K Data (Synthetic)0001689375-26-000052

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026